High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis
暂无分享,去创建一个
B. Gillespie | S. Pennathur | J. Heinecke | M. Kaplan | R. Saran | Anuradha Vivekanandan-Giri | Jaeman Byun | Chongren Tang | R. Sands | Jessica L Slocum
[1] M. Reilly,et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. , 2012, Atherosclerosis.
[2] H. Paulus,et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis , 2012, Annals of the rheumatic diseases.
[3] S. Pennathur,et al. Myeloperoxidase Targets Apolipoprotein A-I, the Major High Density Lipoprotein Protein, for Site-Specific Oxidation in Human Atherosclerotic Lesions* , 2012, The Journal of Biological Chemistry.
[4] S. Pennathur,et al. Myeloperoxidase Targets Apolipoprotein A-I , the Major HDL Protein , for Site-Specific Oxidation in Human Atherosclerotic Lesions , 2012 .
[5] E. Sato,et al. Increased myeloperoxidase plasma levels in rheumatoid arthritis , 2012, Rheumatology International.
[6] G. Francis,et al. Lipid-bound apolipoproteins in tyrosyl radical-oxidized HDL stabilize ABCA1 like lipid-free apolipoprotein A-I , 2012, BMC Biochemistry.
[7] S. Blankenberg,et al. Pathogenic Cycle Between the Endogenous Nitric Oxide Synthase Inhibitor Asymmetrical Dimethylarginine and the Leukocyte-Derived Hemoprotein Myeloperoxidase , 2011, Circulation.
[8] J. Heinecke,et al. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. , 2011, Journal of proteomics.
[9] A. Akhmedov,et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. , 2011, The Journal of clinical investigation.
[10] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[11] P. Toth. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis , 2011 .
[12] S. Pennathur,et al. Quantitative analysis of amino Acid oxidation markers by tandem mass spectrometry. , 2011, Methods in enzymology.
[13] L. Alfredsson,et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006 , 2010, Journal of internal medicine.
[14] Roger E Bumgarner,et al. High-Density Lipoprotein Suppresses the Type I Interferon Response, a Family of Potent Antiviral Immunoregulators, in Macrophages Challenged With Lipopolysaccharide , 2010, Circulation.
[15] W. Robinson,et al. Rheumatoid Arthritis: A Role for Immunosenescence? , 2010, Journal of the American Geriatrics Society.
[16] M. Kaplan. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. , 2010, Rheumatic diseases clinics of North America.
[17] D. Rader,et al. The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[18] D. Symmons,et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis , 2009, Annals of the rheumatic diseases.
[19] H. Paulus,et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. , 2009, Arthritis and rheumatism.
[20] L. Trinquart,et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. , 2009, Rheumatology.
[21] N. Brot,et al. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I , 2008, Proceedings of the National Academy of Sciences.
[22] J. Eiserich,et al. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[23] A. Tall,et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.
[24] B. Fagerberg,et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr Published, JLR Papers in Press, November 18, 2007. , 2008, Journal of Lipid Research.
[25] S. Hazen,et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction , 2007, Nature Structural &Molecular Biology.
[26] B. Hahn,et al. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. , 2007, Journal of autoimmunity.
[27] K. Kalunian,et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[28] H. Klemm,et al. Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase , 2006, Circulation.
[29] J. Voss,et al. Tyrosine 192 in Apolipoprotein A-I Is the Major Site of Nitration and Chlorination by Myeloperoxidase, but Only Chlorination Markedly Impairs ABCA1-dependent Cholesterol Transport* , 2005, Journal of Biological Chemistry.
[30] Michael Kinter,et al. Localization of Nitration and Chlorination Sites on Apolipoprotein A-I Catalyzed by Myeloperoxidase in Human Atheroma and Associated Oxidative Impairment in ABCA1-dependent Cholesterol Efflux from Macrophages* , 2005, Journal of Biological Chemistry.
[31] A. Chait,et al. Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.
[32] A. Chait,et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[33] Michael Kinter,et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.
[34] J. Heinecke,et al. Lysine Residues Direct the Chlorination of Tyrosines in YXXK Motifs of Apolipoprotein A-I When Hypochlorous Acid Oxidizes High Density Lipoprotein* , 2004, Journal of Biological Chemistry.
[35] C. Heeschen,et al. Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.
[36] G L Freeman,et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.
[37] E J Topol,et al. Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.
[38] W. Parks,et al. Hypochlorous Acid Oxygenates the Cysteine Switch Domain of Pro-matrilysin (MMP-7) , 2001, The Journal of Biological Chemistry.
[39] P. Venge,et al. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. , 1999, Rheumatology.
[40] G. Francis,et al. Enhanced Cholesterol Efflux by Tyrosyl Radical-oxidized High Density Lipoprotein Is Mediated by Apolipoprotein AI-AII Heterodimers* , 1998, The Journal of Biological Chemistry.
[41] S. L. Hazen,et al. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.
[42] J. Berliner,et al. The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.
[43] A. Daugherty,et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.
[44] D. Gordon,et al. High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.
[45] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[46] G. Miller,et al. PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.